CN-Bio Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 59

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $34.8M

  • Investors
  • 10

CN-Bio General Information

Description

Developer of a microphysiological system intended for advancing biomedical research and drug development. The company's system replicates the microenvironment of human organs and tissue and incorporates fluidic channels to simulate the flow of nutrients, oxygen, and other biochemical factors, mimicking the physiological conditions of blood circulation in vivo, enabling pharma and biotech companies to improve their effectiveness and efficiency of preclinical drug testing.

Contact Information

Website
www.cn-bio.com
Formerly Known As
Zyoxel, M&R 1070
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 332 Cambridge Science Park
  • Milton Road
  • Cambridge CB4 0WN
  • England, United Kingdom
+44 01223
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • 332 Cambridge Science Park
  • Milton Road
  • Cambridge CB4 0WN
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CN-Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B) 23-Apr-2024 $34.8M Completed Generating Revenue
9. Later Stage VC 01-Sep-2021 Completed Generating Revenue
8. Grant 01-Jan-2021 Completed Generating Revenue
7. Later Stage VC 02-Mar-2020 Completed Generating Revenue
6. Grant 11-Oct-2017 Completed Generating Revenue
5. Later Stage VC 21-Sep-2016 Completed Generating Revenue
4. Later Stage VC 01-Jun-2014 Completed Startup
3. Later Stage VC 10-Jul-2013 Completed Startup
2. Grant $26.3M Completed Startup
1. University Spin-Out 28-Feb-2008 Completed Startup
To view CN-Bio’s complete valuation and funding history, request access »

CN-Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 24,875 $0.012543 $37.63 $37.63 1x $37.63 3.87%
Ordinary 92,421 $0.012543 $41.39 $41.39 1x $41.39 14.37%
To view CN-Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

CN-Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a microphysiological system intended for advancing biomedical research and drug development. The company's
Discovery Tools (Healthcare)
Cambridge, United Kingdom
59 As of 2026

Oegstgeest, Netherlands
 

New Orleans, LA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CN-Bio Competitors (21)

One of CN-Bio’s 21 competitors is MIMETAS, a Venture Capital-Backed company based in Oegstgeest, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MIMETAS Venture Capital-Backed Oegstgeest, Netherlands
28bio Venture Capital-Backed New Orleans, LA
Hesperos Venture Capital-Backed Orlando, FL
Stemnovate Venture Capital-Backed Cambridge, United Kingdom
Brainstorm Cell Therapeutics Corporation New York, NY
You’re viewing 5 of 21 competitors. Get the full list »

CN-Bio Patents

CN-Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025244505-A1 Pumping means for a microfluidic device Pending 28-Mar-2024
GB-202404504-D0 Pumping means for a microfluidic device Pending 28-Mar-2024
GB-2639935-A Pumping means for a microfluidic device Pending 28-Mar-2024
WO-2025202641-A1 Pumping means for a microfluidic device Pending 28-Mar-2024
AU-2025243851-A1 Removable module for the culture of cells in a perfused device Pending 28-Mar-2024 C12M25/04
To view CN-Bio’s complete patent history, request access »

CN-Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CN-Bio Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bayland Capital Corporate Venture Capital Minority
CITIC Capital Asset Manager Minority
GrayBella Capital Venture Capital Minority
CITIC Securities Investment Bank Minority
Pluto Finance (UK) PE-Backed Company Minority
You’re viewing 5 of 10 investors. Get the full list »

CN-Bio FAQs

  • When was CN-Bio founded?

    CN-Bio was founded in 2008.

  • Where is CN-Bio headquartered?

    CN-Bio is headquartered in Cambridge, United Kingdom.

  • What is the size of CN-Bio?

    CN-Bio has 59 total employees.

  • What industry is CN-Bio in?

    CN-Bio’s primary industry is Discovery Tools (Healthcare).

  • Is CN-Bio a private or public company?

    CN-Bio is a Private company.

  • What is the current valuation of CN-Bio?

    The current valuation of CN-Bio is .

  • What is CN-Bio’s current revenue?

    The current revenue for CN-Bio is .

  • How much funding has CN-Bio raised over time?

    CN-Bio has raised $56M.

  • Who are CN-Bio’s investors?

    Bayland Capital, CITIC Capital, GrayBella Capital, CITIC Securities, and Pluto Finance (UK) are 5 of 10 investors who have invested in CN-Bio.

  • Who are CN-Bio’s competitors?

    MIMETAS, 28bio, Hesperos, Stemnovate, and Brainstorm Cell Therapeutics are some of the 21 competitors of CN-Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process